Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

NP001, Alzheimer's Disease, and Blood Markers of Inflammation
Effect of Single Dose NP001 on Blood Markers of Inflammation in Individuals With Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of Hawaii Clinics at Kakaako
mi
from
Honolulu, HI
NP001, Alzheimer's Disease, and Blood Markers of Inflammation
Effect of Single Dose NP001 on Blood Markers of Inflammation in Individuals With Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of Hawaii Clinics at Kakaako
mi
from
Honolulu, HI
Click here to add this to my saved trials
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
ATP Clinical Research, Inc.
mi
from
Costa Mesa, CA
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
ATP Clinical Research, Inc.
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Synergy Research Centers
mi
from
Lemon Grove, CA
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Synergy Research Centers
mi
from
Lemon Grove, CA
Click here to add this to my saved trials
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Collaborative Neuroscience
mi
from
Long Beach, CA
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Collaborative Neuroscience
mi
from
Long Beach, CA
Click here to add this to my saved trials
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Irvine Center for Clinical Research
mi
from
Irvine, CA
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Irvine Center for Clinical Research
mi
from
Irvine, CA
Click here to add this to my saved trials
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Alliance Research
mi
from
Long Beach, CA
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Alliance Research
mi
from
Long Beach, CA
Click here to add this to my saved trials
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Syrentis Clinical Research
mi
from
Santa Ana, CA
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Syrentis Clinical Research
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Varying Risk Factors for Alzheimer's Disease and Subjects on a Ketogenic Diet
Status: Enrolling
Updated:  12/31/1969
Wake Forest School of Medicine
mi
from
Winston-Salem, NC
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Varying Risk Factors for Alzheimer's Disease and Subjects on a Ketogenic Diet
Status: Enrolling
Updated: 12/31/1969
Wake Forest School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Syrentis Clinical Research
mi
from
Santa Ana, CA
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Syrentis Clinical Research
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Brain Matters Research
mi
from
Delray Beach, FL
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Brain Matters Research
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
The Memory Clinic
mi
from
Bennington, VT
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
The Memory Clinic
mi
from
Bennington, VT
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Bioclinica (Compass Research)
mi
from
Orlando, FL
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Bioclinica (Compass Research)
mi
from
Orlando, FL
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Pacific Research Network
mi
from
San Diego, CA
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Pacific Research Network
mi
from
San Diego, CA
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Axiom Clinical Research
mi
from
Tampa, FL
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Axiom Clinical Research
mi
from
Tampa, FL
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Boston Center for Memory
mi
from
Newton, MA
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Boston Center for Memory
mi
from
Newton, MA
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
PMG Research Inc.
mi
from
Winston-Salem, NC
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
PMG Research Inc.
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Abington Neurological Associates
mi
from
Willow Grove, PA
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Abington Neurological Associates
mi
from
Willow Grove, PA
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Toronto Memory Program
mi
from
Toronto,
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Toronto Memory Program
mi
from
Toronto,
Click here to add this to my saved trials
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
Phase 0 Exploratory Study of [18F]MNI-1020 (Also Known as [18F]JNJ-64326067) as an Imaging Marker for Tau Protein in the Brain of Subjects With Alzheimer's Disease Compared to Healthy Subjects
Status: Enrolling
Updated:  12/31/1969
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
Phase 0 Exploratory Study of [18F]MNI-1020 (Also Known as [18F]JNJ-64326067) as an Imaging Marker for Tau Protein in the Brain of Subjects With Alzheimer's Disease Compared to Healthy Subjects
Status: Enrolling
Updated: 12/31/1969
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
Detecting an Early Response to Donepezil With Measures of Visual Attention
Detecting an Early Response to Donepezil With Measures of Visual Attention
Status: Enrolling
Updated:  12/31/1969
Winthrop University Hospital
mi
from
Mineola, NY
Detecting an Early Response to Donepezil With Measures of Visual Attention
Detecting an Early Response to Donepezil With Measures of Visual Attention
Status: Enrolling
Updated: 12/31/1969
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease
Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease
Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Caring for the Caregiver Network
A Tailored Technology Intervention for Diverse Caregivers of AD Patients
Status: Enrolling
Updated:  12/31/1969
University of Miami Miller School of Medicine
mi
from
Miami, FL
Caring for the Caregiver Network
A Tailored Technology Intervention for Diverse Caregivers of AD Patients
Status: Enrolling
Updated: 12/31/1969
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
The Brain Ketone Body Challenge Imaging Study
The Brain Ketone Body Challenge Imaging Study
Status: Enrolling
Updated:  12/31/1969
Wake Forest School of Medicine
mi
from
Winston-Salem, NC
The Brain Ketone Body Challenge Imaging Study
The Brain Ketone Body Challenge Imaging Study
Status: Enrolling
Updated: 12/31/1969
Wake Forest School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
PET Imaging of Subjects Using 124I-PU-AD
PET Imaging of Subjects Using 124I-PU-AD: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering
mi
from
New York, NY
PET Imaging of Subjects Using 124I-PU-AD
PET Imaging of Subjects Using 124I-PU-AD: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering
mi
from
New York, NY
Click here to add this to my saved trials
Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)
Examining the Impact of Photobiomodulation (PBM) on Brain Function in Dementia
Status: Enrolling
Updated:  12/31/1969
San Francisco Veterans Affairs Medical Center
mi
from
San Francisco, CA
Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)
Examining the Impact of Photobiomodulation (PBM) on Brain Function in Dementia
Status: Enrolling
Updated: 12/31/1969
San Francisco Veterans Affairs Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Rancho Research Institute, Rancho Los Amigos National Rehabilitation Center
mi
from
Downey, CA
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Rancho Research Institute, Rancho Los Amigos National Rehabilitation Center
mi
from
Downey, CA
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Medstar Rehabilitation Hospital
mi
from
Washington,
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Medstar Rehabilitation Hospital
mi
from
Washington,
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Shirley Ryan AbilityLab
mi
from
Chicago, IL
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Shirley Ryan AbilityLab
mi
from
Chicago, IL
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Marionjoy Rehabilitation Hospital
mi
from
Wheaton, IL
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Marionjoy Rehabilitation Hospital
mi
from
Wheaton, IL
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Kentucky Clinic
mi
from
Lexington, KY
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Kentucky Clinic
mi
from
Lexington, KY
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Boston Med Ctr
mi
from
Boston, MA
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
New York Presbyterian-Weill Cornell Medical Center
mi
from
New York, NY
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
New York Presbyterian-Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Burke Medical Research Institute
mi
from
White Plains, NY
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Burke Medical Research Institute
mi
from
White Plains, NY
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Helsinki University Central Hospital
mi
from
Helsinki,
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Helsinki University Central Hospital
mi
from
Helsinki,
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
New York Presbyterian Hospital - Columbia University Medical Center
mi
from
New York, NY
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
New York Presbyterian Hospital - Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease
Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease
Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Anchor Neuroscience
mi
from
Pensacola, FL
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Anchor Neuroscience
mi
from
Pensacola, FL
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Alliance Research
mi
from
Long Beach, CA
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Alliance Research
mi
from
Long Beach, CA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Southern California Research, LLC
mi
from
Simi Valley, CA
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Southern California Research, LLC
mi
from
Simi Valley, CA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Miami Dade Medical Research Institute
mi
from
Miami, FL
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Miami Dade Medical Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Sensible Healthcare
mi
from
Ocoee, FL
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Sensible Healthcare
mi
from
Ocoee, FL
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Manhattan Behavioral Medicine, LLC
mi
from
New York, NY
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Manhattan Behavioral Medicine, LLC
mi
from
New York, NY
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Northwest Clinical Research Center
mi
from
Seattle, WA
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Northwest Clinical Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pacific Research Network
mi
from
San Diego, CA
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pacific Research Network
mi
from
San Diego, CA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
CiTrials
mi
from
Santa Ana, CA
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
CiTrials
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Viking Clinical Research
mi
from
Temecula, CA
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Viking Clinical Research
mi
from
Temecula, CA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Progressive Medical Research
mi
from
Port Orange, FL
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Progressive Medical Research
mi
from
Port Orange, FL
Click here to add this to my saved trials